refractory of Selecta. which you and treatment made is completion clinical the We in for for was substantial the I chronic SEL-XXX, the good pivotal appreciate morning. a you highlighted head-to-head Thank lead being year Elona for product enrollment our XXXX joining of us COMPARE today. advancements, candidate, trial developed gout. by
is to with significant which biweekly a of platform once dose to gout. enrollment combines chronic SEL-XXX unmet pegadricase our COMPARE we the of monthly need to believe able seven were trial comparison patients the We months, and trial and in SEL-XXX pegloticase. evaluating ImmTOR refractory in complete the speaks in
three levels The Xmg/dL of patients primary XX% of the acid time. uric maintain who at less and of endpoint six percentage than serum is months the
of expect We this from quarter XXXX. line the third top announce to data trial in
into our monthly SEL-XXX will we immune approved once of we formation of the current with marketplace potential I to a profile As X the that the some could and encouraged the remain antibodies in address dosing Phase unmet which if neutralizing program, without needs system. mitigate shortly, advance the outline strongly suppressing
of a discussion We’re given pleased The with the had and will to us discussed two trials. in months controlled X have program. we the proposed end evaluate month that trial which Phase placebo to contain FDA studies six a study, productive which controlled report placebo design will has of the clarity six January in a the Each expansion consist safety. a we point registrational discussion one clinical extended of on will
each X.X be evaluating per in trials. ImmTOR XX arms placebo ImmTOR FDA, we’ll of be In to kilogram will suggestion placebo per each doses active with arms approximately in of kilogram words, As will one treatment Patients arm. of in X.XX and of the the milligrams the trial. versus of other SEL-XXX. two two two milligrams each randomized patients be in there X-to-X-to-X three per
a X Phase the supply From have perspective, program. to we manufacturing clinical enough commence
report December in XXXX, clinic later program to focus we the our XXXX. into a were broadened therapy support we to and made of with partnership that excited advancements gene continues be which existing Our entry strategic we strategic important all our in AskBio. XXXX In
therapy development option entered to which glycogen AskBio a disease rights is abnormal which called characterized inside genetic, buildup of sugar treatment by AskBio’s in for license exercised is us license lead rare, Pompe tolerance a immune disease, and the for its We disease jointly agreement, molecule indication. use ImmTOR, to a gene lysosomal cells. commercialization and the select that of platform Pompe into storage AAV
Under milestone is in million jointly receive indication we portfolio eligible of payments totaling upfront plus to yet commercialize $XXX with several Selecta million and AskBio the to manufacture, strategic we upon received AAV a have terms sales. payments This $X with indications, academia gene develop, the partnership builds royalties the of agreement, methylmalonic therapies a XXXX on in and other which August announced lead disclosed. product and not of
to platforms in and the in therapies manufacturing partnership concept with technology Our both to of gene redose expertise for in therapeutic currently The expertise biology antibodies therapy clinical against development and there human capsid. AAV utilizing of select important proof will an break-through re-dosing and maybe patients. trial that AAV validate the a redoes be is the due gene immune technology potential companies leverages therapy and gene possible AskBio’s tolerance AAV potential its of a as not to to
AAV been enable tranche gene Pre-clinically, folds, our vector to bringing look dose We first up enhance programs the this and four ImmTOR into dosing and gene has year. with clinic compared to shown to alone. therapy repeat to later forward therapy expression
we updates deficiency, Our later and proprietary this gene intend or on ornithine in therapy program we program includes this year. look advance which to forward transcarbamylase research OTC to providing
new significantly In adding of Directors a to Chairman completing $X to team, our our financial leadership financing. executive XXXX, new appointing we strengthened infrastructure organizations and our several and members million a Board
Chairman many Pharmaceuticals, the successful Humacyte, is of to for healthcare Cox and companies our multiple held Ms. Health, position new Cox and Chair of Cardinal She industry biopharmaceutical several boards renowned executive. the on are biopharmaceutical Array served proud a including among has others. Directors. leader Board have entities, Prism We of Biopharma, as welcomed Carrie and Celgene,
our now Brad? call Dahms. Officer, Brad Financial to the over Chief I'll turn
